{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:48:05Z","timestamp":1787582885212,"version":"build-2736575974"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The purpose of this review is to provide an update on monitoring, prevention, and treatment of infectious and noninfectious complications of phagocytic, humoral, and cellular immune deficiencies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The recognition that immune dysregulatory features are hallmarks of many genetic defects leading to immune deficiency have led to a new name for all congenital disorders that primarily impact immune function \u2013 inborn errors of immunity (IEI). While controlling infections is critical for treatment of patients with IEI, recognition and management of noninfectious complications should also be a focus of comprehensive management of these conditions. Major advances in use of definitive therapies including hematopoietic stem cell transplant, gene therapy, and gene editing have allowed for improved outcomes in cellular and phagocytic immune defects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>There are now over 550 identified IEI, and effective management of these conditions requires a multidisciplinary approach to monitoring, preventing, and treating both infectious and noninfectious complications of IEI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001513","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:00:19Z","timestamp":1762336819000},"page":"606-612","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Management of the child with primary immunodeficiency"],"prefix":"10.1097","volume":"37","author":[{"given":"Heather K.","family":"Lehman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Khaira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simranjit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"R1-20251105","doi-asserted-by":"crossref","first-page":"e20250003","DOI":"10.70962\/jhi.20250003","article-title":"Human inborn errors of immunity: 2024 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"1","author":"Poli","year":"2025","journal-title":"J Hum Immunity"},{"key":"R2-20251105","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jaci.2024.01.011","article-title":"Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data","volume":"153","author":"Rider","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R3-20251105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12016-020-08800-x","article-title":"Chronic granulomatous disease: a comprehensive review","volume":"61","author":"Yu","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"R4-20251105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2500\/aap.2024.45.240049","article-title":"Immunodeficiency: quantitative and qualitative phagocytic cell defects","volume":"45","author":"Mickey","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"R5-20251105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10875-024-01816-4","article-title":"A large cohort from an immunology reference center and an algorithm for the follow-up of chronic neutropenia","volume":"45","author":"Caka","year":"2024","journal-title":"J Clin Immunol"},{"key":"R6-20251105","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaip.2016.03.021","article-title":"A comprehensive approach to the management of children and adults with chronic granulomatous disease","volume":"4","author":"Thomsen","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R7-20251105","doi-asserted-by":"crossref","first-page":"1325.e5","DOI":"10.1016\/j.jaip.2021.12.035","article-title":"Chronic granulomatous disease with inflammatory bowel disease: clinical presentation, treatment, and outcomes from the USIDNET Registry","volume":"10","author":"LaBere","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R8-20251105","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood-2018-11-844563","article-title":"Inflammatory consequences of inherited disorders affecting neutrophil function","volume":"133","author":"Dinauer","year":"2019","journal-title":"Blood"},{"key":"R9-20251105","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"key":"R10-20251105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2014.121608","article-title":"The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis","volume":"100","author":"Bode","year":"2015","journal-title":"Haematologica"},{"key":"R11-20251105","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/blood.2022019586","article-title":"Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD","volume":"142","author":"Leiding","year":"2023","journal-title":"Blood"},{"key":"R12-20251105","doi-asserted-by":"crossref","first-page":"1423.e2","DOI":"10.1016\/j.jaci.2024.01.013","article-title":"Allogeneic hematopoietic cell transplantation is effective for p47phox chronic granulomatous disease: a Primary Immune Deficiency Treatment Consortium study","volume":"153","author":"Grunebaum","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R13-20251105","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41467-022-28762-2","article-title":"A systematic review and meta-analysis of gene therapy with hematopoietic stem and progenitor cells for monogenic disorders","volume":"13","author":"Tucci","year":"2022","journal-title":"Nat Commun"},{"key":"R14-20251105","doi-asserted-by":"crossref","first-page":"eadj6779","DOI":"10.1126\/scitranslmed.adj6779","article-title":"High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease","volume":"16","author":"Bzhilyanskaya","year":"2024","journal-title":"Sci Transl Med"},{"key":"R15-20251105","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jaip.2023.04.001","article-title":"Gene therapy for inborn errors of immunity","volume":"11","author":"Arlabosse","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R16-20251105","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1056\/NEJMoa2407376","article-title":"Lentiviral gene therapy for severe leukocyte adhesion deficiency type 1","volume":"392","author":"Booth","year":"2025","journal-title":"N Engl J Med"},{"key":"R17-20251105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41409-024-02389-x","article-title":"Outcomes in hematopoetic cell transplantation in the setting of mold infections in patients with chronic granulomatous disease","volume":"60","author":"Kline","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"R18-20251105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fimmu.2020.00149","article-title":"Noninfectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis","volume":"11","author":"Ho","year":"2020","journal-title":"Front Immunol"},{"key":"R19-20251105","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/cei.13272","article-title":"British Society for Immunology\/United Kingdom Primary Immunodeficiency Network consensus statement on managing noninfectious complications of common variable immunodeficiency disorders","volume":"196","author":"Bethune","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"R20-20251105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13223-022-00661-7","article-title":"Monitoring patients with uncomplicated common variable immunodeficiency: a systematic review","volume":"18","author":"Lee","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R21-20251105","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"R22-20251105","doi-asserted-by":"crossref","first-page":"1354.e4","DOI":"10.1016\/j.jaci.2010.02.040","article-title":"Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22\u200ayears","volume":"125","author":"Lucas","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R23-20251105","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","article-title":"Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection","volume":"122","author":"Bonagura","year":"2008","journal-title":"J Allergy Clin Immunol"},{"issue":"(Suppl 1)","key":"R24-20251105","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1093\/infdis\/jiad145","article-title":"SARS-CoV-2 infection and response to COVID-19 vaccination in patients with primary immunodeficiencies","volume":"228","author":"Paris","year":"2023","journal-title":"J Infect Dis"},{"key":"R25-20251105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s10875-023-01613-5","article-title":"COVID-19 vaccination in patients with inborn errors of immunity reduces hospitalization and critical care needs related to COVID-19: a USIDNET Report","volume":"44","author":"McDonnell","year":"2024","journal-title":"J Clin Immunol"},{"key":"R26-20251105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"key":"R27-20251105","doi-asserted-by":"crossref","article-title":"Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency","author":"Taghizade","DOI":"10.1016\/j.jaci.2023.08.004"},{"key":"R28-20251105","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R29-20251105","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R30-20251105","doi-asserted-by":"crossref","first-page":"1023127","DOI":"10.3389\/fimmu.2022.1023127","article-title":"Autoimmunity in monogenic combined immune deficiencies with associated or syndromic features","volume":"13","author":"Sharifinejad","year":"2022","journal-title":"Front Immunol"},{"key":"R31-20251105","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.3390\/jcm10204729","article-title":"Autoimmunity in primary immunodeficiency disorders: an updated review on pathogenic and clinical implications","volume":"10","author":"Costagliola","year":"2021","journal-title":"J Clin Med"},{"key":"R32-20251105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaut.2019.01.011","article-title":"Primary immunodeficiency and autoimmunity: a comprehensive review","volume":"99","author":"Amaya-Uribe","year":"2019","journal-title":"J Autoimmun"},{"key":"R33-20251105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"key":"R34-20251105","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0140-6736(23)00731-6","article-title":"Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium","volume":"402","author":"Thakar","year":"2023","journal-title":"Lancet"},{"key":"R35-20251105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10875-020-00865-9","article-title":"Infections in infants with SCID: isolation, infection screening, and prophylaxis in PIDTC Centers","volume":"41","author":"Dorsey","year":"2021","journal-title":"J Clin Immunol"},{"key":"R36-20251105","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/1744666X.2017.1381558","article-title":"Long term outcomes of severe combined immunodeficiency: therapy implications","volume":"13","author":"Heimall","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"R37-20251105","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.jtct.2023.12.148","article-title":"Outcomes following matched sibling donor transplant for severe combined immunodeficiency: a report from the Pidtc","volume":"30","author":"Rayes","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"R38-20251105","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa2206575","article-title":"Lentiviral gene therapy for artemis-deficient SCID","volume":"387","author":"Cowan","year":"2022","journal-title":"N Engl J Med"},{"key":"R39-20251105","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/bloodadvances.2023012079","article-title":"Mending RAG2: gene editing for treatment of RAG2 deficiency","volume":"8","author":"Hicks","year":"2024","journal-title":"Blood Adv"},{"key":"R40-20251105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12016-022-08950-0","article-title":"The treatment of primary immune deficiencies: lessons learned and future opportunities","volume":"65","author":"Paris","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"R41-20251105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10875-024-01710-z","article-title":"Treatment with elapegademase restores immunity in infants with adenosine deaminase deficient severe combined immunodeficiency","author":"Hicks","year":"2024","journal-title":"J Clin Immunol"},{"issue":"(3S)","key":"R42-20251105","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R43-20251105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jaci.2023.09.027","article-title":"Posttransplantation late complications increase over time for patients with SCID: a Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study","volume":"153","author":"Eissa","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R44-20251105","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jaci.2021.12.790","article-title":"An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: a study of a national retrospective cohort of 1375 patients over 10\u200ayears","volume":"149","author":"Alligon","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R45-20251105","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1007\/s10875-020-00857-9","article-title":"Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry","volume":"40","author":"Kuo","year":"2020","journal-title":"J Clin Immunol"},{"key":"R46-20251105","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pediatrneurol.2024.05.022","article-title":"A clinical neurological approach to the child with adenosine deaminase deficiency","volume":"158","author":"Ivarola","year":"2024","journal-title":"Pediatr Neurol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:00:25Z","timestamp":1762336825000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001513","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}